• Title/Summary/Keyword: Medical college

Search Result 30,787, Processing Time 0.042 seconds

Possible Epithelial Ovarian Cancer Association with HPV18 or HPV33 Infection

  • Zhang, Pei-Pei;Zhou, Lei;Cao, Jia-Shi;Li, Yi-Ping;Zeng, Zhi;Sun, Ni;Shen, Li;Zhu, Hao-Yue;Ruan, Yang;Zha, Wen-Ting;Wang, Xin-Yu;Zhang, Ke-Qiang;Zhang, Ran
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.17 no.6
    • /
    • pp.2959-2964
    • /
    • 2016

  • The present study was conducted to investigate the prevalence of HPV infection in epithelial ovarian cancer (EOC) in Hunan province. DNA samples were collected from paraffin embedded ovarian tissue from 322 patients with EOC, 99 with ovarian benign tumors and 199 normal persons. The polymerase chain reaction and direct sequencing were used to identify the HPV types in the samples. The relationship between the infection of human papillomavirus (HPV) and the epithelial ovarian carcinoma (EOC) was investigated combined with clinical data. The prevalence of HPV18 and HPV33 in EOC group and benign group was higher than in the normal group. HPV18 and HPV33 may play a role in the development of both EOC and ovarian benign tumor and may participate in the development of EOC with traditional risk factors, family history and abortion, possibly exerting synergistic effects.

  • KSCI

Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence

  • Nari Kim;Eun Sung Lee;Sang Eun Won;Mihyun Yang;Amy Junghyun Lee;Youngbin Shin;Yousun Ko;Junhee Pyo;Hyo Jung Park;Kyung Won, Kim
    • Korean Journal of Radiology
    • /
    • v.23 no.11
    • /
    • pp.1089-1101
    • /
    • 2022

  • Immunotherapy has revolutionized and opened a new paradigm for cancer treatment. In the era of immunotherapy and molecular targeted therapy, precision medicine has gained emphasis, and an early response assessment is a key element of this approach. Treatment response assessment for immunotherapy is challenging for radiologists because of the rapid development of immunotherapeutic agents, from immune checkpoint inhibitors to chimeric antigen receptor-T cells, with which many radiologists may not be familiar, and the atypical responses to therapy, such as pseudoprogression and hyperprogression. Therefore, new response assessment methods such as immune response assessment, functional/molecular imaging biomarkers, and artificial intelligence (including radiomics and machine learning approaches) have been developed and investigated. Radiologists should be aware of recent trends in immunotherapy development and new response assessment methods.

  • https://doi.org/10.3348/kjr.2022.0225 인용 PDF